Why The DTP Model Is A Win For Drug Manufacturers And Patients
Source: Life Science Leader
By Jay McHarg
Pre-COVID, typically DTP was only a distribution tactic for specialty medicines not generally sold in commercial pharmacies. But similar to telemedicine, once access was greatly diminished, alternatives started to emerge, including curbside pickup and in-town delivery.
VIEW THE MAGAZINE ARTICLE!
Log In
Signing up provides unlimited access to:
Free Sign Up
Signing up provides unlimited access to:
- Trend and Leadership Articles
- Case Studies
- Extensive Product Database
- Premium Content
HELLO. PLEASE LOG IN.
X
Not yet a member of Life Science Leader? Register today.
ACCOUNT SIGN UP
X
Please fill in your account details
ACCOUNT SIGN UP
This website uses cookies to ensure you get the best experience on our website. Learn more